0000899243-22-023336.txt : 20220621 0000899243-22-023336.hdr.sgml : 20220621 20220621160600 ACCESSION NUMBER: 0000899243-22-023336 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220616 FILED AS OF DATE: 20220621 DATE AS OF CHANGE: 20220621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Waksal Harlan CENTRAL INDEX KEY: 0001449008 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39273 FILM NUMBER: 221028164 MAIL ADDRESS: STREET 1: WAKSAL CONSULTING LLC STREET 2: 7 NORTH WILLOW STREET, SUITE 6 CITY: MONTCLAIR STATE: NJ ZIP: 07042 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001327273 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-373-4600 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: 480 Biomedical, Inc. DATE OF NAME CHANGE: 20120927 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Vascular, Inc. DATE OF NAME CHANGE: 20110826 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Medical, Inc. DATE OF NAME CHANGE: 20090414 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-16 0 0001327273 Lyra Therapeutics, Inc. LYRA 0001449008 Waksal Harlan C/O LYRA THERAPEUTICS, INC. 480 ARSENAL WAY WATERTOWN MA 02472 1 1 0 0 Executive Chair Stock Option 5.09 2022-06-16 4 A 0 953002 0.00 A 2032-06-15 Common Stock 953002 953002 D On June 16, 2022, the Reporting Person was granted an option to purchase 953,002 shares of common stock. The option vests and becomes exercisable as to 317,667 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 317,667 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 317,668 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date. /s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D. 2022-06-21